nach oben

Cancer and Metastasis Reviews

Erschienen in:

17.06.2021

Metformin: review of epidemiology and mechanisms of action in pancreatic cancer

verfasst von: Guido Eibl, Enrique Rozengurt

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic ductal adenocarcinoma continues to be a lethal disease, for which efficient treatment options are very limited. Increasing efforts have been taken to understand how to prevent or intercept this disease at an early stage. There is convincing evidence from epidemiologic and preclinical studies that the antidiabetic drug metformin possesses beneficial effects in pancreatic cancer, including reducing the risk of developing the disease and improving survival in patients with early-stage disease. This review will summarize the current literature about the epidemiological data on metformin and pancreatic cancer as well as describe the preclinical evidence illustrating the anticancer effects of metformin in pancreatic cancer. Underlying mechanisms and targets of metformin will also be discussed. These include direct effects on transformed pancreatic epithelial cells and indirect, systemic effects on extra-pancreatic tissues.

Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7–33. https://doi.org/10.3322/caac.21654CrossRef

Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: A Cancer Journal for Clinicians, 66(1), 7–30. https://doi.org/10.3322/caac.21332CrossRef

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research, 74(11), 2913–2921. https://doi.org/10.1158/0008-5472.CAN-14-0155CrossRefPubMed

Albini, A., DeCensi, A., Cavalli, F., & Costa, A. (2016). Cancer prevention and interception: A new era for chemopreventive approaches. Clinical Cancer Research, 22(17), 4322–4327.CrossRefPubMed

Meyskens, F. L., Mukhtar, H., Rock, C. L., Cuzick, J., Kensler, T. W., Yang, C. S., Ramsey, S. D., Lippman, S. M., & Alberts, D. S. (2016). Cancer prevention: Obstacles, challenges, and the road ahead. Journal of the National Cancer Institute, 108(2), djv309. https://doi.org/10.1093/jnci/djv309CrossRefPubMed

Maitra, A., Fukushima, N., Takaori, K., & Hruban, R. H. (2005). Precursors to invasive pancreatic cancer. Advances in Anatomic Pathology, 12(2), 81–91.CrossRefPubMed

Eibl, G., & Rozengurt, E. (2019). KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Seminars in Cancer Biology, 54, 50–62. https://doi.org/10.1016/j.semcancer.2017.10.007CrossRefPubMed

Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., Kawaguchi, Y., Johann, D., Liotta, L. A., Crawford, H. C., Putt, M. E., Jacks, T., Wright, C. V., Hruban, R. H., Lowy, A. M., et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 4(6), 437–450.CrossRefPubMed

Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 7(5), 469–483. https://doi.org/10.1016/j.ccr.2005.04.023CrossRefPubMed

10.

Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016). Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Development, 30(4), 355–385. https://doi.org/10.1101/gad.275776.115CrossRef

11.

Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012). Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. The Journal of Clinical Investigation, 122(2), 639–653. https://doi.org/10.1172/JCI59227CrossRefPubMedPubMedCentral

12.

Arslan, A. A., Helzlsouer, K. J., Kooperberg, C., Shu, X.-O., Steplowski, E., Bueno-de-Mesquita, H. B., Fuchs, C. S., Gross, M. D., Jacobs, E. J., LaCroix, A. Z., Petersen, G. M., Stolzenberg-Solomon, R. Z., Zheng, W., Albanes, D., Amundadottir, L., Bamlet, W. R., Barricarte, A., Bingham, S. A., Boeing, H., et al. (2010). Anthropometric measures, body mass index, and pancreatic cancer: A pooled analysis from the pancreatic cancer cohort consortium (PanScan). Archives of Internal Medicine, 170(9), 791–802. https://doi.org/10.1001/archinternmed.2010.63CrossRefPubMedPubMedCentral

13.

Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010). Diabetes and cancer: A consensus report. CA: A Cancer Journal for Clinicians, 60, 207–221.

14.

Rebours, V., Gaujoux, S., d’Assignies, G., Sauvanet, A., Ruszniewski, P., Lévy, P., Paradis, V., Bedossa, P., & Couvelard, A. (2015). Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN). Clinical Cancer Research, 21(15), 3522–3528. https://doi.org/10.1158/1078-0432.ccr-14-2385CrossRefPubMed

15.

Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016). Body fatness and cancer — viewpoint of the IARC working group. New Engl J Med, 375(8), 794–798. https://doi.org/10.1056/NEJMsr1606602CrossRefPubMed

16.

Bethea, T. N., Kitahara, C. M., Sonderman, J., Patel, A. V., Harvey, C., Knutsen, S. F., Park, Y., Park, S. Y., Fraser, G. E., Jacobs, E. J., Purdue, M. P., Stolzenberg-Solomon, R. Z., Gillanders, E. M., Blot, W. J., Palmer, J. R., & Kolonel, L. N. (2014). A pooled analysis of body mass index and pancreatic cancer mortality in African Americans. Cancer Epidemiology, Biomarkers & Prevention, 23(10), 2119–2125. https://doi.org/10.1158/1055-9965.EPI-14-0422CrossRef

17.

Lega, I. C., & Lipscombe, L. L. (2019). Review: Diabetes, obesity, and cancer—Pathophysiology and clinical implications. Endocrine Reviews, 41(1), 33–52. https://doi.org/10.1210/endrev/bnz014CrossRef

18.

Dawson, D. W., Hertzer, K., Moro, A., Donald, G., Chang, H. H., Go, V. L., Pandol, S. J., Lugea, A., Gukovskaya, A. S., Li, G., Hines, O. J., Rozengurt, E., & Eibl, G. E. (2013). High Fat, high calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prevention Research (Philadelphia, Pa.), 6, 1064–1073.CrossRef

19.

Chang, H.-H., Moro, A., Takakura, K., Su, H.-Y., Mo, A., Nakanishi, M., Waldron, R. T., French, S. W., Dawson, D. W., Hines, O. J., Li, G., Go, V. L. W., Sinnett-Smith, J., Pandol, S. J., Lugea, A., Gukovskaya, A. S., Duff, M. O., Rosenberg, D. W., Rozengurt, E., et al. (2017). Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. PLoS ONE, 12(9), e0184455. https://doi.org/10.1371/journal.pone.0184455CrossRefPubMedPubMedCentral

20.

Lashinger, L. M., Harrison, L. M., Rasmussen, A. J., Logsdon, C. D., Fischer, S. M., McArthur, M. J., & Hursting, S. D. (2013). Dietary energy balance modulation of Kras- and Ink4a/Arf+/–driven pancreatic cancer: The role of insulin-like growth factor-I. Cancer Prevention Research (Philadelphia, Pa.), 6(10), 1046–1055. https://doi.org/10.1158/1940-6207.CAPR-13-0185CrossRef

21.

Philip, B., Roland, C. L., Daniluk, J., Liu, Y., Chatterjee, D., Gomez, S. B., Ji, B., Huang, H., Wang, H., Fleming, J. B., Logsdon, C. D., & Cruz-Monserrate, Z. (2013). A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology, 145(6), 1449–1458. https://doi.org/10.1053/j.gastro.2013.08.018CrossRefPubMed

22.

Chung, K. M., Singh, J., Lawres, L., Dorans, K. J., Garcia, C., Burkhardt, D. B., Robbins, R., Bhutkar, A., Cardone, R., Zhao, X., Babic, A., Vayrynen, S. A., Dias Costa, A., Nowak, J. A., Chang, D. T., Dunne, R. F., Hezel, A. F., Koong, A. C., Wilhelm, J. J., et al. (2020). Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma. Cell, 181(4), 832-847.e818. https://doi.org/10.1016/j.cell.2020.03.062CrossRefPubMedPubMedCentral

23.

Flier, J. S. (2004). Obesity wars: Molecular progress confronts an expanding epidemic. Cell, 116(2), 337–350.CrossRefPubMed

24.

Calle, E. E., & Kaaks, R. (2004). Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nature Reviews Cancer, 4(8), 579–591. https://doi.org/10.1038/nrc1408CrossRefPubMed

25.

Calle, E. E., & Thun, M. J. (2004). Obesity and cancer. Oncogene, 23(38), 6365–6378.CrossRefPubMed

26.

Muoio, D. M., & Newgard, C. B. (2006). Obesity-related derangements in metabolic regulation. Annual Review of Biochemistry, 75, 367–401.CrossRefPubMed

27.

Abbruzzese, J. L., Andersen, D. K., Borrebaeck, C. A. K., Chari, S. T., Costello, E., Cruz-Monserrate, Z., Eibl, G., Engleman, E. G., Fisher, W. E., Habtezion, A., Kim, S. K., Korc, M., Logsdon, C., Lyssiotis, C. A., Pandol, S. J., Rustgi, A., Wolfe, B. M., Zheng, L., & Powers, A. C. (2018). The interface of pancreatic cancer with diabetes, obesity, and inflammation: Research gaps and opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Pancreas, 47(5), 516–525. https://doi.org/10.1097/MPA.0000000000001037CrossRefPubMedPubMedCentral

28.

Andersen, D. K., Andren-Sandberg, A., Duell, E. J., Goggins, M., Korc, M., Petersen, G. M., Smith, J. P., & Whitcomb, D. C. (2013). Pancreatitis-diabetes-pancreatic cancer: Summary of an NIDDK-NCI workshop. Pancreas, 42(8), 1227–1237. https://doi.org/10.1097/MPA.0b013e3182a9ad9dCrossRefPubMed

29.

Andersen, D. K., Korc, M., Petersen, G. M., Eibl, G., Li, D., Rickels, M. R., Chari, S. T., & Abbruzzese, J. L. (2017). Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes, 66(5), 1103–1110. https://doi.org/10.2337/db16-1477CrossRefPubMedPubMedCentral

30.

Eibl, G., Cruz-Monserrate, Z., Korc, M., Petrov, M. S., Goodarzi, M. O., Fisher, W. E., Habtezion, A., Lugea, A., Pandol, S. J., Hart, P. A., Andersen, D. K., & Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic, Cancer. (2018). Diabetes mellitus and obesity as risk factors for pancreatic cancer. Journal of the Academy of Nutrition and Dietetics, 118(4), 555–567. https://doi.org/10.1016/j.jand.2017.07.005CrossRefPubMed

31.

Kahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005). AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism, 1(1), 15–25. https://doi.org/10.1016/j.cmet.2004.12.003CrossRefPubMed

32.

Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010). Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. The Journal of Clinical Investigation, 120(7), 2355–2369. https://doi.org/10.1172/jci40671CrossRefPubMedPubMedCentral

33.

Wu, T., Horowitz, M., & Rayner, C. K. (2017). New insights into the anti-diabetic actions of metformin: From the liver to the gut. Expert Review of Gastroenterology & Hepatology, 11(2), 157–166. https://doi.org/10.1080/17474124.2017.1273769CrossRef

34.

Rena, G., Hardie, D. G., & Pearson, E. R. (2017). The mechanisms of action of metformin. Diabetologia, 60(9), 1577–1585. https://doi.org/10.1007/s00125-017-4342-zCrossRefPubMedPubMedCentral

35.

Duca, F. A., Côté, C. D., Rasmussen, B. A., Zadeh-Tahmasebi, M., Rutter, G. A., Filippi, B. M., & Lam, T. K. (2015). Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nature Medicine, 21(5), 506–511. https://doi.org/10.1038/nm.3787CrossRefPubMedPubMedCentral

36.

Li, D., Yeung, S. C., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009). Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 137(2), 482–488. https://doi.org/10.1053/j.gastro.2009.04.013CrossRefPubMed

37.

de Jong, R. G., Burden, A. M., de Kort, S., van Herk-Sukel, M. P., Vissers, P. A., Janssen, P. K., Haak, H. R., Masclee, A. A., de Vries, F., & Janssen-Heijnen, M. L. (2017). No decreased risk of gastrointestinal cancers in users of metformin in the netherlands; a time-varying analysis of metformin exposure. Cancer Prevention Research (Philadelphia, Pa.), 10(5), 290–297. https://doi.org/10.1158/1940-6207.CAPR-16-0277CrossRef

38.

Decensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010). Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prevention Research (Philadelphia, Pa.), 3(11), 1451–1461. https://doi.org/10.1158/1940-6207.CAPR-10-0157CrossRef

39.

Zhang, P., Li, H., Tan, X., Chen, L., & Wang, S. (2013). Association of metformin use with cancer incidence and mortality: A meta-analysis. Cancer Epidemiology, 37(3), 207–218. https://doi.org/10.1016/j.canep.2012.12.009CrossRefPubMed

40.

Yu, H., Zhong, X., Gao, P., Shi, J., Wu, Z., Guo, Z., Wang, Z., & Song, Y. (2019). The potential effect of metformin on cancer: An umbrella review. Front Endocrinol (Lausanne), 10, 617. https://doi.org/10.3389/fendo.2019.00617CrossRef

41.

Sadeghi, N., Abbruzzese, J. L., Yeung, S. C., Hassan, M., & Li, D. (2012). Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clinical Cancer Research, 18(10), 2905–2912. https://doi.org/10.1158/1078-0432.CCR-11-2994CrossRefPubMedPubMedCentral

42.

Jang, W. I., Kim, M. S., Kang, S. H., Jo, A. J., Kim, Y. J., Tchoe, H. J., Park, C. M., Kim, H. J., Choi, J. A., Choi, H. J., Paik, E. K., Seo, Y. S., Yoo, H. J., Kang, J. K., Han, C. J., Kim, Y. J., Kim, S. B., & Ko, M. J. (2017). Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea. Oncotarget, 8(6), 9587–9596. https://doi.org/10.18632/oncotarget.14525CrossRefPubMed

43.

Chaiteerakij, R., Petersen, G. M., Bamlet, W. R., Chaffee, K. G., Zhen, D. B., Burch, P. A., Leof, E. R., Roberts, L. R., & Oberg, A. L. (2016). Metformin use and survival of patients with pancreatic cancer: A cautionary lesson. Journal of Clinical Oncology, 34(16), 1898–1904. https://doi.org/10.1200/JCO.2015.63.3511CrossRefPubMedPubMedCentral

44.

Kordes, S., Pollak, M. N., Zwinderman, A. H., Mathot, R. A., Weterman, M. J., Beeker, A., Punt, C. J., Richel, D. J., & Wilmink, J. W. (2015). Metformin in patients with advanced pancreatic cancer: A double-blind, randomised, placebo-controlled phase 2 trial. The lancet Oncology, 16(7), 839–847. https://doi.org/10.1016/S1470-2045(15)00027-3CrossRefPubMed

45.

Zhou, P. T., Li, B., Liu, F. R., Zhang, M. C., Wang, Q., Li, Y. Y., Xu, C., Liu, Y. H., Yao, Y., & Li, D. (2017). Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: A systematic review and meta-analysis. Oncotarget, 8(15), 25242–25250. https://doi.org/10.18632/oncotarget.15692CrossRefPubMedPubMedCentral

46.

Shi, Y. Q., Zhou, X. C., Du, P., Yin, M. Y., Xu, L., Chen, W. J., & Xu, C. F. (2020). Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis. Medicine (Baltimore), 99(37), e21687. https://doi.org/10.1097/MD.0000000000021687CrossRef

47.

Yoo, D., Kim, N., Hwang, D. W., Song, K. B., Lee, J. H., Lee, W., Kwon, J., Park, Y., Hong, S., Lee, J. W., Hwang, K., Shin, D., Tak, E., & Kim, S. C. (2020). Association between metformin use and clinical outcomes following pancreaticoduodenectomy in patients with type 2 diabetes and pancreatic ductal adenocarcinoma. Journal of Clinical Medicine, 9(6), E1953. https://doi.org/10.3390/jcm9061953CrossRefPubMed

48.

Wei, M., Liu, Y., Bi, Y., & Zhang, Z. J. (2019). Metformin and pancreatic cancer survival: Real effect or immortal time bias? International Journal of Cancer, 145(7), 1822–1828. https://doi.org/10.1002/ijc.32254CrossRefPubMed

49.

Tamburrino, D., Guarneri, G., Pagnanelli, M., Crippa, S., Partelli, S., Belfiori, G., Capurso, G., & Falconi, M. (2021). Chemopreventive agents after pancreatic resection for ductal adenocarcinoma: Legend or scientific evidence? Annals of Surgical Oncology, 28(4), 2312–2322. https://doi.org/10.1245/s10434-020-09097-yCrossRefPubMed

50.

Kim, J., Bae, Y. J., Lee, J. W., Kim, Y. S., Kim, Y., You, H. S., Kim, H. S., Choi, E. A., Han, Y. E., & Kang, H. T. (2021). Metformin use in cancer survivors with diabetes reduces all-cause mortality, based on the Korean National Health Insurance Service between 2002 and 2015. Medicine (Baltimore), 100(11), e25045. https://doi.org/10.1097/MD.0000000000025045CrossRef

51.

Li, X., Li, T., Liu, Z., Gou, S., & Wang, C. (2017). The effect of metformin on survival of patients with pancreatic cancer: A meta-analysis. Science and Reports, 7(1), 5825. https://doi.org/10.1038/s41598-017-06207-xCrossRef

52.

Schneider, M. B., Matsuzaki, H., Haorah, J., Ulrich, A., Standop, J., Ding, X. Z., Adrian, T. E., & Pour, P. M. (2001). Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology, 120(5), 1263–1270. https://doi.org/10.1053/gast.2001.23258CrossRefPubMed

53.

Cifarelli, V., Lashinger, L. M., Devlin, K. L., Dunlap, S. M., Huang, J., Kaaks, R., Pollak, M. N., & Hursting, S. D. (2015). Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms. Diabetes, 64(5), 1632–1642. https://doi.org/10.2337/db14-1132CrossRefPubMedPubMedCentral

54.

Yue, W., Zheng, X., Lin, Y., Yang, C. S., Xu, Q., Carpizo, D., Huang, H., DiPaola, R. S., & Tan, X. L. (2015). Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget, 6(25), 21208–21224. https://doi.org/10.18632/oncotarget.4126CrossRefPubMedPubMedCentral

55.

Incio, J., Suboj, P., Chin, S. M., Vardam-Kaur, T., Liu, H., Hato, T., Babykutty, S., Chen, I., Deshpande, V., Jain, R. K., & Fukumura, D. (2015). Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophages. PLoS ONE, 10(12), e0141392. https://doi.org/10.1371/journal.pone.0141392CrossRefPubMedPubMedCentral

56.

Kato, K., Iwama, H., Yamashita, T., Kobayashi, K., Fujihara, S., Fujimori, T., Kamada, H., Kobara, H., & Masaki, T. (2016). The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin. Oncology Reports, 35(3), 1582–1592. https://doi.org/10.3892/or.2015.4496CrossRefPubMed

57.

Shi, Y., He, Z., Jia, Z., & Xu, C. (2016). Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo. Molecular Medicine Reports, 14(4), 2921–2928. https://doi.org/10.3892/mmr.2016.5592CrossRefPubMedPubMedCentral

58.

Wang, C., Zhang, T., Liao, Q., Dai, M., Guo, J., Yang, X., Tan, W., Lin, D., Wu, C., & Zhao, Y. (2021). Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Protein & Cell, 12(2), 128–144. https://doi.org/10.1007/s13238-020-00760-4CrossRef

59.

Rajeshkumar, N. V., Yabuuchi, S., Pai, S. G., De Oliveira, E., Kamphorst, J. J., Rabinowitz, J. D., Tejero, H., Al-Shahrour, F., Hidalgo, M., Maitra, A., & Dang, C. V. (2017). Treatment of pancreatic cancer patient-derived xenograft panel with metabolic inhibitors reveals efficacy of phenformin. Clinical Cancer Research, 23(18), 5639–5647. https://doi.org/10.1158/1078-0432.CCR-17-1115CrossRefPubMedPubMedCentral

60.

Lipner, M. B., Marayati, R., Deng, Y., Wang, X., Raftery, L., O’Neil, B. H., & Yeh, J. J. (2016). Metformin treatment does not inhibit growth of pancreatic cancer patient-derived xenografts. PLoS ONE, 11(1), e0147113. https://doi.org/10.1371/journal.pone.0147113CrossRefPubMedPubMedCentral

61.

Kisfalvi, K., Eibl, G., Sinnett-Smith, J., & Rozengurt, E. (2009). Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Research, 69(16), 6539–6545. https://doi.org/10.1158/0008-5472.CAN-09-0418CrossRefPubMedPubMedCentral

62.

Kisfalvi, K., Moro, A., Sinnett-Smith, J., Eibl, G., & Rozengurt, E. (2013). Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas, 42(5), 781–785. https://doi.org/10.1097/MPA.0b013e31827aec40CrossRefPubMed

63.

Tan, X. L., Bhattacharyya, K. K., Dutta, S. K., Bamlet, W. R., Rabe, K. G., Wang, E., Smyrk, T. C., Oberg, A. L., Petersen, G. M., & Mukhopadhyay, D. (2015). Metformin suppresses pancreatic tumor growth with inhibition of NFkappaB/STAT3 inflammatory signaling. Pancreas, 44(4), 636–647. https://doi.org/10.1097/MPA.0000000000000308CrossRefPubMedPubMedCentral

64.

Chen, K., Qian, W., Jiang, Z., Cheng, L., Li, J., Sun, L., Zhou, C., Gao, L., Lei, M., Yan, B., Cao, J., Duan, W., & Ma, Q. (2017). Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Molecular Cancer, 16(1), 131. https://doi.org/10.1186/s12943-017-0701-0CrossRefPubMedPubMedCentral

65.

Qian, W., Li, J., Chen, K., Jiang, Z., Cheng, L., Zhou, C., Yan, B., Cao, J., Ma, Q., & Duan, W. (2018). Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sciences, 208, 253–261. https://doi.org/10.1016/j.lfs.2018.07.046CrossRefPubMed

66.

Chang, H. H., Moro, A., Chou, C. E. N., Dawson, D. W., French, S., Schmidt, A. I., Sinnett-Smith, J., Hao, F., Hines, O. J., Eibl, G., & Rozengurt, E. (2018). Metformin decreases the incidence of pancreatic ductal adenocarcinoma promoted by diet-induced obesity in the conditional KrasG12D mouse model. Science and Reports, 8(1), 5899. https://doi.org/10.1038/s41598-018-24337-8CrossRef

67.

Dong, T. S., Chang, H. H., Hauer, M., Lagishetty, V., Katzka, W., Rozengurt, E., Jacobs, J. P., & Eibl, G. (2019). Metformin alters the duodenal microbiome and decreases the incidence of pancreatic ductal adenocarcinoma promoted by diet-induced obesity. American Journal of Physiology. Gastrointestinal and Liver Physiology, 317(6), G763–G772. https://doi.org/10.1152/ajpgi.00170.2019CrossRefPubMedPubMedCentral

68.

Eibl, G. (2020). Endocrine-exocrine signals in obesity-associated pancreatic cancer. Nature Reviews. Gastroenterology & Hepatology, 17(8), 455–456. https://doi.org/10.1038/s41575-020-0324-6CrossRef

69.

Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014). Metformin: From mechanisms of action to therapies. Cell Metabolism, 20(6), 953–966. https://doi.org/10.1016/j.cmet.2014.09.018CrossRefPubMed

70.

Pollak, M. (2017). The effects of metformin on gut microbiota and the immune system as research frontiers. Diabetologia, 60(9), 1662–1667. https://doi.org/10.1007/s00125-017-4352-xCrossRefPubMed

71.

Pollak, M. N. (2012). Investigating metformin for cancer prevention and treatment: The end of the beginning. Cancer Discovery, 2(9), 778–790. https://doi.org/10.1158/2159-8290.CD-12-0263CrossRefPubMed

72.

Pollak, M. (2010). Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prevention Research (Philadelphia, Pa.), 3(9), 1060–1065. https://doi.org/10.1158/1940-6207.CAPR-10-0175CrossRef

73.

Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., Goldspink, D. A., Miedzybrodzka, E. L., Konopka, A. R., Esponda, R. R., Huang, J. T., Tung, Y. C. L., Rodriguez-Cuenca, S., Tomaz, R. A., Harding, H. P., et al. (2020). GDF15 mediates the effects of metformin on body weight and energy balance. Nature, 578(7795), 444–448. https://doi.org/10.1038/s41586-019-1911-yCrossRefPubMed

74.

Rozengurt, E., & Eibl, G. (2019). Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. World Journal of Gastroenterology, 25(15), 1797–1816. https://doi.org/10.3748/wjg.v25.i15.1797CrossRefPubMedPubMedCentral

75.

Foretz, M., Guigas, B., & Viollet, B. (2019). Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews. Endocrinology, 15(10), 569–589. https://doi.org/10.1038/s41574-019-0242-2CrossRefPubMed

76.

Hawley, S. A., Ross, F. A., Chevtzoff, C., Green, K. A., Evans, A., Fogarty, S., Towler, M. C., Brown, L. J., Ogunbayo, O. A., Evans, A. M., & Hardie, D. G. (2010). Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metabolism, 11(6), 554–565. https://doi.org/10.1016/j.cmet.2010.04.001CrossRefPubMedPubMedCentral

77.

Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27(25), 3576–3586. https://doi.org/10.1038/sj.onc.1211024CrossRefPubMed

78.

Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brule, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., Marette, A., Kozma, S. C., & Thomas, G. (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metabolism, 11(5), 390–401. https://doi.org/10.1016/j.cmet.2010.03.014CrossRefPubMedPubMedCentral

79.

LaMoia, T. E., & Shulman, G. I. (2021). Cellular and molecular mechanisms of metformin action. Endocrine Reviews, 42(1), 77–96. https://doi.org/10.1210/endrev/bnaa023CrossRefPubMed

80.

Wang, L. W., Li, Z. S., Zou, D. W., Jin, Z. D., Gao, J., & Xu, G. M. (2008). Metformin induces apoptosis of pancreatic cancer cells. World Journal of Gastroenterology, 14(47), 7192–7198. https://doi.org/10.3748/wjg.14.7192CrossRefPubMedPubMedCentral

81.

Bao, B., Wang, Z., Ali, S., Ahmad, A., Azmi, A. S., Sarkar, S. H., Banerjee, S., Kong, D., Li, Y., Thakur, S., & Sarkar, F. H. (2012). Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prevention Research (Philadelphia, Pa.), 5(3), 355–364. https://doi.org/10.1158/1940-6207.CAPR-11-0299CrossRef

82.

Nair, V., Sreevalsan, S., Basha, R., Abdelrahim, M., Abudayyeh, A., Rodrigues Hoffman, A., & Safe, S. (2014). Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: Role of specificity protein (Sp) transcription factors. Journal of Biological Chemistry, 289(40), 27692–27701. https://doi.org/10.1074/jbc.M114.592576CrossRefPubMedPubMedCentral

83.

Yan, Y., Zhou, X. E., Xu, H. E., & Melcher, K. (2018). Structure and Physiological Regulation of AMPK. International Journal of Molecular Sciences, 19(11), 3534. https://doi.org/10.3390/ijms19113534CrossRefPubMedCentral

84.

Hardie, D. G. (2015). AMPK: Positive and negative regulation, and its role in whole-body energy homeostasis. Current Opinion in Cell Biology, 33, 1–7. https://doi.org/10.1016/j.ceb.2014.09.004CrossRefPubMed

85.

Olivier, S., Foretz, M., & Viollet, B. (2018). Promise and challenges for direct small molecule AMPK activators. Biochem Pharmacol, 153, 147–158. https://doi.org/10.1016/j.bcp.2018.01.049CrossRefPubMed

86.

Hezel, A. F., & Bardeesy, N. (2008). LKB1; linking cell structure and tumor suppression. Oncogene, 27(55), 6908–6919. https://doi.org/10.1038/onc.2008.342CrossRefPubMed

87.

Bridges, H. R., Jones, A. J., Pollak, M. N., & Hirst, J. (2014). Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. The Biochemical Journal, 462(3), 475–487. https://doi.org/10.1042/bj20140620CrossRefPubMed

88.

Pryor, R., & Cabreiro, F. (2015). Repurposing metformin: An old drug with new tricks in its binding pockets. The Biochemical Journal, 471(3), 307–322. https://doi.org/10.1042/bj20150497CrossRefPubMed

89.

Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012). AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology, 13(4), 251–262.CrossRefPubMedPubMedCentral

90.

Ming, M., Sinnett-Smith, J., Wang, J., Soares, H. P., Young, S. H., Eibl, G., & Rozengurt, E. (2014). Dose-dependent AMPK-dependent and independent mechanisms of berberine and metformin inhibition of mTORC1, ERK, DNA synthesis and proliferation in pancreatic cancer cells. PLoS ONE, 9(12), e114573. https://doi.org/10.1371/journal.pone.0114573CrossRefPubMedPubMedCentral

91.

Sinnett-Smith, J., Kisfalvi, K., Kui, R., & Rozengurt, E. (2013). Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: Dependence on glucose concentration and role of AMPK. Biochemical and Biophysical Research Communications, 430(1), 352–357. https://doi.org/10.1016/j.bbrc.2012.11.010CrossRefPubMed

92.

Carroll, B., & Dunlop, E. A. (2017). The lysosome: A crucial hub for AMPK and mTORC1 signalling. The Biochemical Journal, 474(9), 1453–1466. https://doi.org/10.1042/BCJ20160780CrossRefPubMed

93.

Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006). Critical nodes in signalling pathways: Insights into insulin action. Nature Reviews Molecular Cell Biology, 7(2), 85–96.CrossRefPubMed

94.

Rozengurt, E. (2014). Mechanistic target of rapamycin (mTOR): A point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. Frontiers in Physiology, 5, 357. https://doi.org/10.3389/fphys.2014.00357CrossRefPubMedPubMedCentral

95.

Rozengurt, E., Soares, H. P., & Sinnet-Smith, J. (2014). Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: An unintended consequence leading to drug resistance. Molecular Cancer Therapeutics, 13(11), 2477–2488. https://doi.org/10.1158/1535-7163.mct-14-0330CrossRefPubMedPubMedCentral

96.

Soares, H. P., Ni, Y., Kisfalvi, K., Sinnett-Smith, J., & Rozengurt, E. (2013). Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS ONE, 8(2), e57289. https://doi.org/10.1371/journal.pone.0057289CrossRefPubMedPubMedCentral

97.

Soares, H. P., Ming, M., Mellon, M., Young, S. H., Han, L., Sinnet-Smith, J., & Rozengurt, E. (2015). Dual PI3K/mTOR inhibitors induce rapid overactivation of the MEK/ERK pathway in human pancreatic cancer cells through suppression of mTORC2. Molecular Cancer Therapeutics, 14(4), 1014–1023. https://doi.org/10.1158/1535-7163.mct-14-0669CrossRefPubMedPubMedCentral

98.

Lee, J. W., Park, S., Takahashi, Y., & Wang, H.-G. (2010). The association of AMPK with ULK1 regulates autophagy. PLoS ONE, 5(11), e15394.CrossRefPubMedPubMedCentral

99.

Saxton, R. A., & Sabatini, D. M. (2017). mTOR signaling in growth, metabolism, and disease. Cell, 168(6), 960–976. https://doi.org/10.1016/j.cell.2017.02.004CrossRefPubMedPubMedCentral

100.

Um, S. H., D’Alessio, D., & Thomas, G. (2006). Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metabolism, 3(6), 393–402.CrossRefPubMed

101.

Ali, S. M., & Sabatini, D. M. (2005). Structure of S6 kinase 1 determines whether Raptor-mTOR or Rictor-mTOR phosphorylates its hydrophobic motif site. Journal of Biological Chemistry, 280, 19445–19448.CrossRefPubMed

102.

Long, X., Muller, F., & Avruch, J. (2004). TOR action in mammalian cells and in Caenorhabditis elegans. Current Topics in Microbiology and Immunology, 279, 115–138.PubMed

103.

Armengol, G., Rojo, F., Castellvi, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J., & Ramon y Cajal, S. . (2007). 4E-binding protein 1: A key molecular “funnel factor” in human cancer with clinical implications. Cancer Research, 67(16), 7551–7555.CrossRefPubMed

104.

Inoki, K., Zhu, T., & Guan, K. L. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115(5), 577–590. https://doi.org/10.1016/s0092-8674(03)00929-2CrossRefPubMed

105.

Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004). The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 6(1), 91–99. https://doi.org/10.1016/j.ccr.2004.06.007CrossRefPubMed

106.

Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., Wang, C. Y., He, X., MacDougald, O. A., You, M., Williams, B. O., & Guan, K. L. (2006). TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell, 126(5), 955–968. https://doi.org/10.1016/j.cell.2006.06.055CrossRefPubMed

107.

Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular Cell, 30(2), 214–226. https://doi.org/10.1016/j.molcel.2008.03.003CrossRefPubMedPubMedCentral

108.

Tzatsos, A., & Tsichlis, P. N. (2007). Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. Journal of Biological Chemistry, 282(25), 18069–18082. https://doi.org/10.1074/jbc.M610101200CrossRefPubMed

109.

Ning, J., & Clemmons, D. R. (2010). AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Molecular Endocrinology, 24(6), 1218–1229. https://doi.org/10.1210/me.2009-0474CrossRefPubMedPubMedCentral

110.

Piccolo, S., Dupont, S., & Cordenonsi, M. (2014). The biology of YAP/TAZ: Hippo signaling and beyond. Physiological Reviews, 94(4), 1287–1312. https://doi.org/10.1152/physrev.00005.2014CrossRefPubMed

111.

Yu, F. X., Zhao, B., & Guan, K. L. (2015). Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell, 163(4), 811–828. https://doi.org/10.1016/j.cell.2015.10.044CrossRefPubMedPubMedCentral

112.

Enzo, E., Santinon, G., Pocaterra, A., Aragona, M., Bresolin, S., Forcato, M., Grifoni, D., Pession, A., Zanconato, F., Guzzo, G., Bicciato, S., & Dupont, S. (2015). Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J, 34(10), 1349–1370. https://doi.org/10.15252/embj.201490379CrossRefPubMedPubMedCentral

113.

Wang, Z., Wu, Y., Wang, H., Zhang, Y., Mei, L., Fang, X., Zhang, X., Zhang, F., Chen, H., Liu, Y., Jiang, Y., Sun, S., Zheng, Y., Li, N., & Huang, L. (2014). Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A, 111(1), E89-98. https://doi.org/10.1073/pnas.1319190110CrossRefPubMed

114.

Santinon, G., Pocaterra, A., & Dupont, S. (2016). Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways. Trends in Cell Biology, 26(4), 289–299. https://doi.org/10.1016/j.tcb.2015.11.004CrossRefPubMed

115.

Ardestani, A., Lupse, B., & Maedler, K. (2018). Hippo signaling: Key emerging pathway in cellular and whole-body metabolism. Trends in Endocrinology and Metabolism , 29(7), 492–509. https://doi.org/10.1016/j.tem.2018.04.006CrossRefPubMed

116.

Koo, J. H., & Guan, K. L. (2018). Interplay between YAP/TAZ and Metabolism. Cell Metabolism, 28(2), 196–206. https://doi.org/10.1016/j.cmet.2018.07.010CrossRefPubMed

117.

Plouffe, S. W., Lin, K. C., Moore, J. L., 3rd., Tan, F. E., Ma, S., Ye, Z., Qiu, Y., Ren, B., & Guan, K. L. (2018). The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. Journal of Biological Chemistry, 293(28), 11230–11240. https://doi.org/10.1074/jbc.RA118.002715CrossRefPubMedPubMedCentral

118.

Callus, B. A., Finch-Edmondson, M. L., Fletcher, S., & Wilton, S. D. (2019). YAPping about and not forgetting TAZ. FEBS Letters, 593(3), 253–276. https://doi.org/10.1002/1873-3468.13318CrossRefPubMed

119.

Zhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, E. E., Laughlin, S. Z., Wadhwa, M., Chetram, M., Joshi, M., Wang, F., Kallakury, B., Toretsky, J., Wellstein, A., & Yi, C. (2014). Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Science Signaling, 7(324), ra42. https://doi.org/10.1126/scisignal.2005049CrossRefPubMedPubMedCentral

120.

Gruber, R., Panayiotou, R., Nye, E., Spencer-Dene, B., Stamp, G., & Behrens, A. (2016). YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. Gastroenterology, 151(3), 526–539. https://doi.org/10.1053/j.gastro.2016.05.006CrossRefPubMed

121.

Tu, B., Yao, J., Ferri-Borgogno, S., Zhao, J., Chen, S., Wang, Q., Yan, L., Zhou, X., Zhu, C., Bang, S., Chang, Q., Bristow, C. A., Kang, Y., Zheng, H., Wang, H., Fleming, J. B., Kim, M., Heffernan, T. P., Draetta, G. F., et al. (2019). YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight, 4(21), e130811. https://doi.org/10.1172/jci.insight.130811CrossRefPubMedCentral

122.

Rozengurt, E., Sinnett-Smith, J., & Eibl, G. (2018). Yes-associated protein (YAP) in pancreatic cancer: At the epicenter of a targetable signaling network associated with patient survival. Signal Transduction and Targeted Therapy, 3, 11. https://doi.org/10.1038/s41392-017-0005-2CrossRefPubMedPubMedCentral

123.

Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C. J., Sadanandam, A., Hu, B., Chang, Q., Chu, G. C., Al-Khalil, R., Jiang, S., Xia, H., Fletcher-Sananikone, E., Lim, C., Horwitz, G. I., Viale, A., et al. (2014). Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell, 158(1), 185–197. https://doi.org/10.1016/j.cell.2014.06.003CrossRefPubMedPubMedCentral

124.

Yang, S., Zhang, L., Purohit, V., Shukla, S. K., Chen, X., Yu, F., Fu, K., Chen, Y., Solheim, J., Singh, P. K., Song, W., & Dong, J. (2015). Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget, 6(34), 36019–36031. https://doi.org/10.18632/oncotarget.5935CrossRefPubMedPubMedCentral

125.

Morvaridi, S., Dhall, D., Greene, M. I., Pandol, S. J., & Wang, Q. (2015). Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. Science and Reports, 5, 16759. https://doi.org/10.1038/srep16759CrossRef

126.

Murakami, S., Shahbazian, D., Surana, R., Zhang, W., Chen, H., Graham, G. T., White, S. M., Weiner, L. M., & Yi, C. (2017). Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene, 36(9), 1232–1244. https://doi.org/10.1038/onc.2016.288CrossRefPubMed

127.

Mueller, S., Engleitner, T., Maresch, R., Zukowska, M., Lange, S., Kaltenbacher, T., Konukiewitz, B., Ollinger, R., Zwiebel, M., Strong, A., Yen, H. Y., Banerjee, R., Louzada, S., Fu, B., Seidler, B., Gotzfried, J., Schuck, K., Hassan, Z., Arbeiter, A., et al. (2018). Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature, 554(7690), 62–68. https://doi.org/10.1038/nature25459CrossRefPubMedPubMedCentral

128.

Hajimoradi Javarsiani, M., Sajedianfard, J., & Haghjooy Javanmard, S. (2020). The effects of metformin on the hippo pathway in the proliferation of melanoma cancer cells: a preclinical study. Archives of Physiology and Biochemistry, pp, 1–6. https://doi.org/10.1080/13813455.2020.1760304.

129.

Liu, J., Li, J., Chen, H., Wang, R., Li, P., Miao, Y., & Liu, P. (2020). Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway. Journal of Cellular and Molecular Medicine, 24(10), 5786–5796. https://doi.org/10.1111/jcmm.15241CrossRefPubMedPubMedCentral

130.

Jin, D., Guo, J., Wu, Y., Chen, W., Du, J., Yang, L., Wang, X., Gong, K., Dai, J., Miao, S., Li, X., & Su, G. (2020). Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis. Journal of Experimental & Clinical Cancer Research, 39(1), 6. https://doi.org/10.1186/s13046-019-1503-6CrossRef

131.

Wu, Y., Zheng, Q., Li, Y., Wang, G., Gao, S., Zhang, X., Yan, X., Zhang, X., Xie, J., Wang, Y., Sun, X., Meng, X., Yin, B., & Wang, B. (2019). Metformin targets a YAP1-TEAD4 complex via AMPKalpha to regulate CCNE1/2 in bladder cancer cells. Journal of Experimental & Clinical Cancer Research, 38(1), 376. https://doi.org/10.1186/s13046-019-1346-1CrossRef

132.

Yuan, X., Wei, W., Bao, Q., Chen, H., Jin, P., & Jiang, W. (2018). Metformin inhibits glioma cells stemness and epithelial-mesenchymal transition via regulating YAP activity. Biomedicine & Pharmacotherapy, 102, 263–270. https://doi.org/10.1016/j.biopha.2018.03.031CrossRef

133.

Tian, Y., Tang, B., Wang, C., Sun, D., Zhang, R., Luo, N., Han, Z., Liang, R., Gao, Z., & Wang, L. (2016). Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. Oncotarget, 7(29), 46230–46241. https://doi.org/10.18632/oncotarget.10079CrossRefPubMedPubMedCentral

134.

Mo, J. S., Meng, Z., Kim, Y. C., Park, H. W., Hansen, C. G., Kim, S., Lim, D. S., & Guan, K. L. (2015). Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nature Cell Biology, 17(4), 500–510. https://doi.org/10.1038/ncb3111CrossRefPubMedPubMedCentral

135.

Wang, W., Xiao, Z. D., Li, X., Aziz, K. E., Gan, B., Johnson, R. L., & Chen, J. (2015). AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nature Cell Biology, 17(4), 490–499. https://doi.org/10.1038/ncb3113CrossRefPubMedPubMedCentral

136.

Omkumar, R. V., Darnay, B. G., & Rodwell, V. W. (1994). Modulation of Syrian hamster 3-hydroxy-3-methylglutaryl-CoA reductase activity by phosphorylation. Role of serine 871. J Biol Chem, 269(9), 6810–6814.CrossRefPubMed

137.

Moroishi, T., Hansen, C. G., & Guan, K. L. (2015). The emerging roles of YAP and TAZ in cancer. Nature Reviews Cancer, 15(2), 73–79. https://doi.org/10.1038/nrc3876CrossRefPubMedPubMedCentral

138.

DeRan, M., Yang, J., Shen, C. H., Peters, E. C., Fitamant, J., Chan, P., Hsieh, M., Zhu, S., Asara, J. M., Zheng, B., Bardeesy, N., Liu, J., & Wu, X. (2014). Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Reports, 9(2), 495–503. https://doi.org/10.1016/j.celrep.2014.09.036CrossRefPubMed

139.

Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho, R. A., Montminy, M., & Cantley, L. C. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310(5754), 1642–1646. https://doi.org/10.1126/science.1120781CrossRefPubMedPubMedCentral

140.

Berker, B., Emral, R., Demirel, C., Corapcioglu, D., Unlu, C., & Kose, K. (2004). Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy. Gynecological Endocrinology, 19(3), 125–133. https://doi.org/10.1080/09513590400007309CrossRefPubMed

141.

Goodwin, P. J., Pritchard, K. I., Ennis, M., Clemons, M., Graham, M., & Fantus, I. G. (2008). Insulin-lowering effects of metformin in women with early breast cancer. Clinical Breast Cancer, 8(6), 501–505. https://doi.org/10.3816/CBC.2008.n.060CrossRefPubMed

142.

Mutgan, A. C., Besikcioglu, H. E., Wang, S., Friess, H., Ceyhan, G. O., & Demir, I. E. (2018). Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer. Molecular Cancer, 17(1), 66. https://doi.org/10.1186/s12943-018-0806-0CrossRefPubMedPubMedCentral

143.

Zheng, Y., Wu, C., Yang, J., Zhao, Y., Jia, H., Xue, M., Xu, D., Yang, F., Fu, D., Wang, C., Hu, B., Zhang, Z., Li, T., Yan, S., Wang, X., Nelson, P. J., Bruns, C., Qin, L., & Dong, Q. (2020). Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Signal Transduction and Targeted Therapy, 5(1), 53. https://doi.org/10.1038/s41392-020-0146-6CrossRefPubMedPubMedCentral

144.

Trajkovic-Arsic, M., Kalideris, E., & Siveke, J. T. (2013). The role of insulin and IGF system in pancreatic cancer. Journal of Molecular Endocrinology, 50(3), R67-74. https://doi.org/10.1530/JME-12-0259CrossRefPubMed

145.

Renehan, A. G., Frystyk, J., & Flyvbjerg, A. (2006). Obesity and cancer risk: The role of the insulin-IGF axis. Trends in Endocrinology and Metabolism , 17(8), 328–336. https://doi.org/10.1016/j.tem.2006.08.006CrossRefPubMed

146.

Subramani, R., Lopez-Valdez, R., Arumugam, A., Nandy, S., Boopalan, T., & Lakshmanaswamy, R. (2014). Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis. PLoS ONE, 9(5), e97016. https://doi.org/10.1371/journal.pone.0097016CrossRefPubMedPubMedCentral

147.

Gong, J., Robbins, L. A., Lugea, A., Waldron, R. T., Jeon, C. Y., & Pandol, S. J. (2014). Diabetes, pancreatic cancer, and metformin therapy. Frontiers in Physiology, 5, 426. https://doi.org/10.3389/fphys.2014.00426CrossRefPubMedPubMedCentral

148.

Hao, F., Xu, Q., Zhao, Y., Stevens, J. V., Young, S. H., Sinnett-Smith, J., & Rozengurt, E. (2017). Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells. Molecular Cancer Research, 15(7), 929–941. https://doi.org/10.1158/1541-7786.MCR-17-0023CrossRefPubMed

149.

Rozengurt, E., Sinnett-Smith, J., & Kisfalvi, K. (2010). Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: A novel target for the antidiabetic drug metformin in pancreatic cancer. Clinical Cancer Research, 16(9), 2505–2511. https://doi.org/10.1158/1078-0432.CCR-09-2229CrossRefPubMedPubMedCentral

150.

Liu, S. S., Ma, X. F., Zhao, J., Du, S. X., Zhang, J., Dong, M. Z., & Xin, Y. N. (2020). Association between nonalcoholic fatty liver disease and extrahepatic cancers: A systematic review and meta-analysis. Lipids in Health and Disease, 19(1), 118. https://doi.org/10.1186/s12944-020-01288-6CrossRefPubMedPubMedCentral

151.

Chang, C. F., Tseng, Y. C., Huang, H. H., Shih, Y. L., Hsieh, T. Y., & Lin, H. H. (2018). Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. Internal and Emergency Medicine, 13(2), 191–197. https://doi.org/10.1007/s11739-017-1774-xCrossRefPubMed

152.

Murphy, N., Jenab, M., & Gunter, M. J. (2018). Adiposity and gastrointestinal cancers: Epidemiology, mechanisms and future directions. Nature Reviews. Gastroenterology & Hepatology, 15(11), 659–670. https://doi.org/10.1038/s41575-018-0038-1CrossRef

153.

Maruvada, P., Leone, V., Kaplan, L. M., & Chang, E. B. (2017). The Human Microbiome and Obesity: Moving beyond Associations. Cell Host & Microbe, 22(5), 589–599. https://doi.org/10.1016/j.chom.2017.10.005CrossRef

154.

Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444(7122), 1027–1031. https://doi.org/10.1038/nature05414CrossRefPubMed

155.

He, L. (2020). Metformin and Systemic Metabolism. Trends in Pharmacological Sciences, 41(11), 868–881. https://doi.org/10.1016/j.tips.2020.09.001CrossRefPubMedPubMedCentral

156.

Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., Pedersen, H. K., Arumugam, M., Kristiansen, K., Voigt, A. Y., Vestergaard, H., Hercog, R., Costea, P. I., Kultima, J. R., Li, J., Jorgensen, T., et al. (2015). Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature, 528(7581), 262–266. https://doi.org/10.1038/nature15766CrossRefPubMedPubMedCentral

157.

Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Manneras-Holm, L., Stahlman, M., Olsson, L. M., Serino, M., Planas-Felix, M., Xifra, G., Mercader, J. M., Torrents, D., Burcelin, R., Ricart, W., Perkins, R., Fernandez-Real, J. M., & Backhed, F. (2017). Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine, 23(7), 850–858. https://doi.org/10.1038/nm.4345CrossRefPubMed

158.

Shin, N. R., Lee, J. C., Lee, H. Y., Kim, M. S., Whon, T. W., Lee, M. S., & Bae, J. W. (2014). An increase in the Akkermansia spp population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut, 63(5), 727–735. https://doi.org/10.1136/gutjnl-2012-303839CrossRefPubMed

159.

Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin, I., Chandra, V., San Lucas, A., Scheet, P., Xu, H., Hanash, S. M., Feng, L., Burks, J. K., Do, K. A., Peterson, C. B., Nejman, D., Tzeng, C. D., et al. (2019). Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell, 178(4), 795-806.e712. https://doi.org/10.1016/j.cell.2019.07.008CrossRefPubMedPubMedCentral

160.

Sethi, V., Kurtom, S., Tarique, M., Lavania, S., Malchiodi, Z., Hellmund, L., Zhang, L., Sharma, U., Giri, B., Garg, B., Ferrantella, A., Vickers, S. M., Banerjee, S., Dawra, R., Roy, S., Ramakrishnan, S., Saluja, A., & Dudeja, V. (2018). Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response. Gastroenterology, 155(1), 33-37.e36. https://doi.org/10.1053/j.gastro.2018.04.001CrossRefPubMed

161.

Pushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C. P., Kurz, E., Mishra, A., Mohan, N., Aykut, B., Usyk, M., Torres, L. E., Werba, G., Zhang, K., Guo, Y., Li, Q., Akkad, N., Lall, S., Wadowski, B., Gutierrez, J., Kochen Rossi, J. A., et al. (2018). The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discovery, 8(4), 403–416. https://doi.org/10.1158/2159-8290.CD-17-1134CrossRefPubMedPubMedCentral

162.

Mannucci, E., Tesi, F., Bardini, G., Ognibene, A., Petracca, M. G., Ciani, S., Pezzatini, A., Brogi, M., Dicembrini, I., Cremasco, F., Messeri, G., & Rotella, C. M. (2004). Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes, Nutrition & Metabolism, 17(6), 336–342.

163.

Napolitano, A., Miller, S., Nicholls, A. W., Baker, D., Van Horn, S., Thomas, E., Rajpal, D., Spivak, A., Brown, J. R., & Nunez, D. J. (2014). Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS ONE, 9(7), e100778. https://doi.org/10.1371/journal.pone.0100778CrossRefPubMedPubMedCentral

164.

Duca, F. A., Bauer, P. V., Hamr, S. C., & Lam, T. K. (2015). Glucoregulatory Relevance of Small Intestinal Nutrient Sensing in Physiology, Bariatric Surgery, and Pharmacology. Cell Metabolism, 22(3), 367–380. https://doi.org/10.1016/j.cmet.2015.07.003CrossRefPubMed

165.

Yang, M., Darwish, T., Larraufie, P., Rimmington, D., Cimino, I., Goldspink, D. A., Jenkins, B., Koulman, A., Brighton, C. A., Ma, M., Lam, B. Y. H., Coll, A. P., O’Rahilly, S., Reimann, F., & Gribble, F. M. (2021). Inhibition of mitochondrial function by metformin increases glucose uptake, glycolysis and GDF-15 release from intestinal cells. Science and Reports, 11(1), 2529. https://doi.org/10.1038/s41598-021-81349-7CrossRef

Titel: Metformin: review of epidemiology and mechanisms of action in pancreatic cancer
verfasst von: Guido Eibl
Enrique Rozengurt
Publikationsdatum: 17.06.2021
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2021
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-021-09977-z

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Metformin: review of epidemiology and mechanisms of action in pancreatic cancer

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Models of pancreatic ductal adenocarcinoma

The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions

Targeting KRAS in pancreatic cancer: new drugs on the horizon

Preface

Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners

Targeting DNA damage repair pathways in pancreas cancer

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie